Tığlı Aydın R Seda, Kaynak Gökçe, Gümüşderelioğlu Menemşe
Department of Biomedical Engineering, Bülent Ecevit University, İncivez, Zonguldak, 67100, Turkey.
Bioengineering Division, Hacettepe University, Beytepe, Ankara, Turkey.
J Biomed Mater Res A. 2016 Feb;104(2):455-64. doi: 10.1002/jbm.a.35591. Epub 2015 Oct 28.
Salinomycin has been introduced as a novel alternative to traditional anti-cancer drugs. The aim of this study was to test a strategy designed to deliver salinomycin to glioblastoma cells in vitro. Salinomycin-encapsulated polysorbate 80-coated poly(lactic-co-glycolic acid) nanoparticles (P80-SAL-PLGA) were prepared and characterized with respect to particle size, morphology, thermal properties, drug encapsulation efficiency and controlled salinomycin-release behaviour. The in vitro cellular uptake of P80-SAL-PLGA (5 and 10 µM) or uncoated nanoparticles was assessed in T98G human glioblastoma cells, and the cell viability was investigated with respect to anti-growth activities. SAL, which was successfully transported to T98G glioblastoma cells via P80 coated nanoparticles (∼14% within 60 min), greatly decreased (p < 0.01) the cellular viability of T98G cells. Substantial morphological changes were observed in the T98G cells with damaged actin cytoskeleton. Thus, P80-SAL-PLGA nanoparticles induced cell death, suggesting a potential therapeutic role for this salinomycin delivery system in the treatment of human glioblastoma.
沙利霉素已作为传统抗癌药物的一种新型替代品被引入。本研究的目的是测试一种旨在将沙利霉素体外递送至胶质母细胞瘤细胞的策略。制备了包裹有沙利霉素的聚山梨酯80包衣的聚（乳酸-乙醇酸）纳米颗粒（P80-SAL-PLGA），并对其粒径、形态、热性能、药物包封率和沙利霉素的控释行为进行了表征。在T98G人胶质母细胞瘤细胞中评估了P80-SAL-PLGA（5和10μM）或未包衣纳米颗粒的体外细胞摄取情况，并研究了细胞活力的抗生长活性。通过P80包被的纳米颗粒成功转运至T98G胶质母细胞瘤细胞的SAL（60分钟内约14%），显著降低（p < 0.01）了T98G细胞的细胞活力。在肌动蛋白细胞骨架受损的T98G细胞中观察到明显的形态变化。因此，P80-SAL-PLGA纳米颗粒诱导细胞死亡，表明该沙利霉素递送系统在治疗人类胶质母细胞瘤中具有潜在的治疗作用
